Featuring perspectives from Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi A Jänne, Dr Suresh S Ramalingam, Dr Joshua K Sabari and Dr Helena Yu, moderated by Dr Yu, including the following topics:

• Introduction (0:00)
• Evolving First-Line Treatment for Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) — Dr Yu (1:47)
• EGFR-Targeted Approaches for Relapsed EGFR-Mutant NSCLC; Strategies to Facilitate Delivery of Recently Approved Agents — Dr Sabari (23:48)
• Potential Utility of TROP2-Targeted Therapy in the Management of EGFR-Mutant NSCLC — Dr Ramalingam (45:16)
• Contemporary Care for Patients with Nonmetastatic EGFR-Mutant NSCLC — Dr Goldman (1:03:56)
• Current and Future Management of EGFR Exon 20 Mutation-Positive NSCLC — Prof Girard (1:24:40)
• Emerging Role of HER3-Targeted Therapy in the Management of EGFR-Mutant NSCLC — Dr Jänne (1:43:46)

CME information and select publications

Featuring perspectives from Dr Geoffrey Y Ku and Dr Zev Wainberg, including the following topics:

• Introduction: ASCO Preview (0:00)
• HER2-Positive Gastroesophageal Cancers (19:03)
• Immunotherapy in HER2-Negative Advanced Gastroesophageal Cancers (36:11)
• Immunotherapy in Microsatellite Instability-High Gastroesophageal Cancers (44:04)
• CLDN18.2-Positive Advanced Gastroesophageal Cancers (51:30)

CME information and select publications

Featuring perspectives from Prof Meletios-Athanasios (Thanos) C Dimopoulos and Dr Robert Z Orlowski, including the following topics:

• Introduction: ASCO 2025 Preview (0:00)
• Anti-CD38 Antibodies (10:12)
• Belantamab Mafodotin (29:45)
• CAR T-Cell Therapy (40:57)
• Bispecific Antibodies (47:33)
• Other Novel Agents (56:46)

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma | Faculty Presentation 2: Chimeric Antigen Receptor (CAR) T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) — Meletios-Athanasios (Thanos) C Dimopoulos, MD

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma | Faculty Presentation 1: Current and Emerging Therapeutic Approaches for Multiple Myeloma (MM) — Robert Z Orlowski, MD, PhD

CME information and select publications

Featuring perspectives from Dr Virginia F Borges, Ms Jamie Carroll, Mr Ronald Stein and Dr Seth Wander, including the following topics:

• Introduction (0:00)
• Role of CDK4/6 Inhibitors in Localized and Metastatic Hormone Receptor (HR)-Positive Breast Cancer (12:49)
• PI3K Inhibition as First-Line Treatment for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) (38:24)
• Clinical Utility of AKT and PI3K Inhibitors in Progressive HR-Positive mBC (1:01:44)
• Current and Future Role of Oral Selective Estrogen Receptor Degraders in HR-Positive mBC (1:24:38)

NCPD information and select publications

Featuring perspectives from Prof Claire Harrison and Dr John Mascarenhas, including the following topics:

Introduction (0:00)

• New Biology of Myelofibrosis (1:55)
• Novel Regulatory T-Cell Infusion Therapy (14:57)
• Myelofibrosis 2025: JAK Inhibitors (Ruxolitinib) (20:39)
• BET Inhibitors: Pelabresib (42:03)
• Navtemadlin (53:20)

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Myelofibrosis | Faculty Presentation 2: Novel Investigational Strategies — John Mascarenhas, MD

CME information and select publications